Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

16.25EUR
23 Oct 2017
Change (% chg)

-- (--)
Prev Close
€16.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
257,533
52-wk High
€18.28
52-wk Low
€8.21

Select another date:

Fri, Oct 20 2017

BRIEF-Ablynx NV offers 9.2 million of its ordinary shares in global offering

* Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing

BRIEF-Ablynx to offer and sell about $175 million of its ordinary shares

* ‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​

BRIEF-Ablynx establishes subsidiary in USA

* ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ablynx NV files for U.S. IPO of up to $150 mln

* Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

Belgian biotech Ablynx scores big hit with blood disease drug

Oct 2 Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

BRIEF-Ablynx announces positive topline results of Phase III Hercules study of Caplacizumab

* ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

BRIEF-Ablynx lowers net cash burn guidance for the full year 2017

* ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE

BRIEF-Ablynx announces warrant exercise

* AS A RESULT OF THIS TRANSACTION, ABLYNX NOW HAS 61,169,732 SHARES OUTSTANDING

BRIEF-Ablynx receives FDA fast track designation for Caplacizumab

* ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

Select another date: